Literature DB >> 34176310

Role of Complement Component 3 in Early Erythrolysis in the Hematoma After Experimental Intracerebral Hemorrhage.

Ming Wang1,2, Fan Xia1, Shu Wan1,2, Ya Hua1, Richard F Keep1, Guohua Xi1.   

Abstract

Background and Purpose: Early erythrolysis occurs within the hematoma following intracerebral hemorrhage (ICH), and the release of erythrocyte cytoplasmic proteins such as hemoglobin and Prx2 (peroxiredoxin 2) can cause brain injury. Complement activation can induce erythrolysis. This study determined the function of complement component 3 (C3) in erythrolysis in hematoma and brain injury after ICH in mice.
Methods: This study has 3 parts. First, ICH was induced in adult male C3-sufficient and deficient mice and animals were euthanized on days 1, 3, 7, and 28 for immunohistochemistry after magnetic resonance imaging and behavioral testing. Second, C3-sufficient and deficient mice with ICH were euthanized on day 1 for Western blot analysis. Third, C3-sufficient mice received injections of PBS and Prx2. Mice underwent both magnetic resonance imaging and behavioral tests on day 1 and were then euthanized. Brains were harvested for immunohistochemistry and Fluoro-Jade C staining.
Results: Erythrolysis occurred in the hematoma in C3-sufficient and deficient mice on day 3 following ICH. C3-deficient mice had less erythrolysis, brain swelling, and neuronal degeneration in the acute phase and less brain atrophy in the chronic phase. There were fewer neurological deficits on days 3, 7, and 28 in C3-deficient mice. C3-deficient mice also had less extracellular Prx2 release. Moreover, Prx2 induced brain edema and brain injury and recruited macrophage scavenger receptor-1- and CD4-positive cells following ICH in mice. Conclusions: C3-deficient mice had less severe erythrolysis and brain injury following ICH compared with C3-sufficient mice. Prx2 released after erythrolysis can cause brain damage and neuroinflammation in mice.

Entities:  

Keywords:  atrophy; brain; hematoma; hemoglobin; mice

Mesh:

Substances:

Year:  2021        PMID: 34176310      PMCID: PMC8316397          DOI: 10.1161/STROKEAHA.121.034372

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   10.170


  35 in total

1.  Reconstitution of Ca(2+)-dependent K+ transport in erythrocyte membrane vesicles requires a cytoplasmic protein.

Authors:  R B Moore; M V Mankad; S K Shriver; V N Mankad; G A Plishker
Journal:  J Biol Chem       Date:  1991-10-05       Impact factor: 5.157

2.  Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration.

Authors:  L C Schmued; C Albertson; W Slikker
Journal:  Brain Res       Date:  1997-03-14       Impact factor: 3.252

3.  Complement Inhibition Attenuates Early Erythrolysis in the Hematoma and Brain Injury in Aged Rats.

Authors:  Ming Wang; Ya Hua; Richard F Keep; Shu Wan; Nemanja Novakovic; Guohua Xi
Journal:  Stroke       Date:  2019-06-10       Impact factor: 7.914

4.  Intracerebral Hemorrhage-Induced Brain Injury in Rats: the Role of Extracellular Peroxiredoxin 2.

Authors:  Liheng Bian; Jingwei Zhang; Ming Wang; Richard F Keep; Guohua Xi; Ya Hua
Journal:  Transl Stroke Res       Date:  2019-07-04       Impact factor: 6.829

Review 5.  Intracerebral haemorrhage: mechanisms of injury and therapeutic targets.

Authors:  Richard F Keep; Ya Hua; Guohua Xi
Journal:  Lancet Neurol       Date:  2012-06-13       Impact factor: 44.182

6.  Hematoma Changes During Clot Resolution After Experimental Intracerebral Hemorrhage.

Authors:  Shenglong Cao; Mingzhe Zheng; Ya Hua; Gao Chen; Richard F Keep; Guohua Xi
Journal:  Stroke       Date:  2016-04-28       Impact factor: 7.914

7.  Targeted complement inhibition salvages stressed neurons and inhibits neuroinflammation after stroke in mice.

Authors:  Ali Alawieh; E Farris Langley; Stephen Tomlinson
Journal:  Sci Transl Med       Date:  2018-05-16       Impact factor: 17.956

8.  The role of complement C3 in intracerebral hemorrhage-induced brain injury.

Authors:  Shuxu Yang; Takehiro Nakamura; Ya Hua; Richard F Keep; John G Younger; Yangdong He; Julian T Hoff; Guohua Xi
Journal:  J Cereb Blood Flow Metab       Date:  2006-03-22       Impact factor: 6.200

9.  Role of lipocalin-2 in extracellular peroxiredoxin 2-induced brain swelling, inflammation and neuronal death.

Authors:  Jingwei Zhang; Nemanja Novakovic; Ya Hua; Richard F Keep; Guohua Xi
Journal:  Exp Neurol       Date:  2020-10-29       Impact factor: 5.330

10.  Intra-hematomal White Matter Tracts Act As a Scaffold for Macrophage Infiltration After Intracerebral Hemorrhage.

Authors:  Jingyin Chen; Sravanthi Koduri; Shuhui Dai; Yasunori Toyota; Ya Hua; Neeraj Chaudhary; Aditya S Pandey; Richard F Keep; Guohua Xi
Journal:  Transl Stroke Res       Date:  2020-10-22       Impact factor: 6.800

View more
  4 in total

1.  NLRP3 Inflammasome Overactivation in Patients with Aneurysmal Subarachnoid Hemorrhage.

Authors:  Elena Díaz-García; Kapil Nanwani-Nanwani; Sara García-Tovar; Enrique Alfaro; Eduardo López-Collazo; Manuel Quintana-Díaz; Francisco García-Rio; Carolina Cubillos-Zapata
Journal:  Transl Stroke Res       Date:  2022-07-11       Impact factor: 6.800

Review 2.  The Fate of Erythrocytes after Cerebral Hemorrhage.

Authors:  Fan Xia; Richard F Keep; Fenghui Ye; Katherine G Holste; Shu Wan; Guohua Xi; Ya Hua
Journal:  Transl Stroke Res       Date:  2022-01-23       Impact factor: 6.800

Review 3.  Role of Eryptosis in Hemorrhagic Stroke.

Authors:  Mei Fang; Fan Xia; Yuqi Chen; Yuke Shen; Lu Ma; Chao You; Chuanyuan Tao; Xin Hu
Journal:  Front Mol Neurosci       Date:  2022-07-28       Impact factor: 6.261

4.  Role of complement C1q/C3-CR3 signaling in brain injury after experimental intracerebral hemorrhage and the effect of minocycline treatment.

Authors:  Yonghe Zheng; Linfeng Fan; Siqi Xia; Qiguo Yang; Zhihua Zhang; Huaijun Chen; Hanhai Zeng; Xiongjie Fu; Yucong Peng; Chaoran Xu; Kaibo Yu; Fuyi Liu; Shenglong Cao
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.